HSD3B1

Caris Life Sciences to Showcase Extensive Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at ASCO 2024

Retrieved on: 
Tuesday, May 14, 2024
SCLC, Lung, Patient, Prognosis, Doctor of Philosophy, Immunotherapy, POA, PIWIL1, Diagnosis, Neoplasm, Endometrial cancer, TP53, Carcinoma, Breast cancer, NSCLC, Prostate, MBA, MD, Prostate cancer, Abstract, Research, Cancer, Biomarker, ASCO, CRC, Data analysis, Lung cancer, Medicine, ESR1, RNA, Society, Hepatocellular carcinoma, Genotype, Breast, NCI, HSD3B1, Annual general meeting, Medical imaging

IRVING, Texas, May 14, 2024 /PRNewswire/ -- Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from the biopharma industry and leading cancer centers, including those within the Caris Precision Oncology Alliance™ (POA), will collectively present 41 studies across 19 tumor types at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting May 31 to June 4, 2024 (Booth #28001). The findings demonstrate the power of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • Through extensive sequencing and data analysis efforts, we're unlocking new avenues for tailored therapies to revolutionize cancer treatment."
  • (Abstract Number: 8088)
    Poster and abstract summaries highlighting the Caris research presented at ASCO 2024 will be available onsite at Caris' Booth 28001.
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.
  • POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.

Caris Life Sciences to Present Research at the 2024 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Tuesday, January 23, 2024
Neutrophil, PST, Research, Overalls, Prostate cancer, Androgen receptor, University, Cancer, NCI, Prognosis, Metastasis, FACP, Transcriptome, MHC, Abstract, Diagnosis, Medicine, MYC, NK, Neoplasm, MAPK, DNA, Survival, HSD3B1, Disease, Drug development, ADT, E2F, Liver, PIM, Urachal cancer, Lung, POA, Physician, Renal cell carcinoma, PCA, B cell, Poster, RCC, Escape Room, AI, Immunotherapy, Recurrence, MBA, Prostate, Phenotype, PIM1, Gene expression, IL-6, Huntsman Cancer Institute, Patient, MD, Metadata, ASCO, WSP, C7, Society, PSA, FDA, NEPC, Vaccine

IRVING, Texas, Jan. 23, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present eight studies across four tumor types at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, January 25-27, 2024 in San Francisco. The findings demonstrate the continued and expanded capabilities of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • That's a major focus of the wide array of research Caris and our POA collaborators will proudly present at this year's ASCO GU."
  • The research is a collaboration with the Huntsman Cancer Institute at the University of Utah and other POA members.
  • Caris will present additional data from studies demonstrating the critical role of comprehensive molecular profiling in the treatment of genitourinary cancers.
  • The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Retrieved on: 
Tuesday, May 17, 2022
Phenotype, CRPC, BTK, Pain, Risk, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Postherpetic neuralgia, TKI, SNP, Patient, RPF, PHN, Vaccine, Antibody, Bone, RECIST, Phase, Therapy, MCRPC, Trial of the century, FDA, SAN, IND, Partnership, Prostate cancer, Toxicity, Osteoarthritis, Autoimmune disease, Safety, Forward-looking statement, HSD3B1, EGFR, TRPV1, Phosphorylation, CAGR, RTX, Cancer, Castration, Sciatica, Security (finance), Neoplasm, Annual report, GLOBE, Pharmaceutical industry, Pet, Generic drug, COVID-19

FDA granted IND clearance for Abivertinib (Fujovee) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.

Key Points: 
  • FDA granted IND clearance for Abivertinib (Fujovee) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.
  • The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-nave and abiraterone-progressing mCRPC.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.